Head and Neck Neoplasm

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM).

PMID 21351275 · Liu et al., 2010 · Open in CIViC

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001).

PMID 16533790 · Salvatore et al., 2006 · Open in CIViC

Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC)

PMID 24987354 · Ali et al., 2014 · Open in CIViC

In an 80 year old female anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification o… (full text at CIViC)

PMID 27532222 · Prager et al., 2016 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a conjunctival malignant melanoma patient harboring a BRAF V600E mutation, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification of the BRAF V600E mutation, the … (full text at CIViC)

PMID 27520988 · Maleka et al., 2016 · Open in CIViC

In a retrospective study of 17 papillary thyroid cancer patients, patients with BRAF V600E mutation (n=6) were associated with a 47% (7/15) partial response rate and a 53% (8/15) stable disease rate.

PMID 25353071 · Dadu et al., 2015 · Open in CIViC

In a clinical trial (NCT01286753) of 55 cancer patients with BRAF V600E mutation, patients with metastatic papillary thyroid cancer (n=3) were associated with sensitivity to vemurafenib treatment. One… (full text at CIViC)

PMID 23489023 · Kim et al., 2013 · Open in CIViC

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to vemurafenib than those with wildtype BRAF (IC50: 0.115� 1.156 uM vs. 56.674�1349.788 uM).

PMID 18458053 · Sala et al., 2008 · Open in CIViC

In an in vitro study, BRAF V600E expressing cell lines (BCPAP, OCUT1, K1 and SW1736) demonstrated increased sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells (FTC133, K… (full text at CIViC)

PMID 21185263 · Xing et al., 2011 · Open in CIViC

In an in vitro study, the BCPAP cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability and apoptoti… (full text at CIViC)

PMID 26456083 · Byeon et al., 2016 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC)

PMID 23406047 · Rosove et al., 2013 · Open in CIViC

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.

PMID 16309541 · Thomas et al., 2005 · Open in CIViC

Study observed the effects of ribociclib (LEE011) on anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) cells. qRT-PCR found Cyclin D1 mRNA to have significantly higher expression in A… (full text at CIViC)

PMID 29306020 · Lee et al., 2018 · Open in CIViC

Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). … (full text at CIViC)

PMID 27086918 · Chowdhury et al., 2016 · Open in CIViC

In a Clinic Phase 2 Consortium, 44 patients with metastatic nasopharyngeal carcinoma had an overall response rate (ORR) to nivolumab of 20.5%; 1 complete response lasting over 12 months; 8 partial res… (full text at CIViC)

PMID 29584545 · Ma et al., 2018 · Open in CIViC

In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC)

PMID 25751671 · Aso et al., 2015 · Open in CIViC

41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response … (full text at CIViC)

PMID 24239278 · Moreno-Galindo et al., 2014 · Open in CIViC

720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to p… (full text at CIViC)

PMID 20530316 · Ang et al., 2010 · Open in CIViC

p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.

PMID 24799460 · Argiris et al., 2014 · Open in CIViC

Validating predominant overexpression of DDR2 in 554 head and neck squamous cell carcinoma (HNSCC) patients indicated the potentiality of utilizing dasatinib as a DDR2 inhibitor. From these patients, … (full text at CIViC)

PMID 27434411 · von Mässenhausen et al., 2016 · Open in CIViC

The primary tumor of A patient with head and neck squamous cell carcinoma with lung metastasis was not surgically resectable. Initial treatments led to stable disease and progression after 1 year. The… (full text at CIViC)

PMID 31011208 · Yang et al., 2019 · Open in CIViC

An analysis of 13 infants with pituitary blastoma (age 7-24 months) demonstrated recurrent DICER1 mutations. Of those with samples available for sequencing, 9 of 9 (100%) had germline DICER1 mutation… (full text at CIViC)

PMID 24839956 · de Kock et al., 2014 · Open in CIViC

This 2021 paper analyzed the outcomes and complications of 17 patients with pituitary blastoma. The median age of diagnosis was 11 months with a range of 2-24 months. Germline DICER1 variants were… (full text at CIViC)

PMID 33236116 · Liu et al., 2021 · Open in CIViC

A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome ana… (full text at CIViC)

PMID 31871216 · Majounie et al., 2020 · Open in CIViC

3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC)

PMID 25677871 · Ansell et al., 2016 · Open in CIViC

The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC)

PMID 16943533 · Chung et al., 2006 · Open in CIViC

This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and dis… (full text at CIViC)

PMID 17538160 · Temam et al., 2007 · Open in CIViC

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC)

PMID 23265711 · Licitra et al., 2013 · Open in CIViC

bp] In an in vitro study, a NIH3T3 cell line expressing EGFR P546S mutation demonstrated increased sensitivity to cetuximab treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity w… (full text at CIViC)

PMID 23578570 · Bahassi et al., 2013 · Open in CIViC

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. One case of … (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC